Open Orphan Plc (GB:HVO) has released an update.
hVIVO plc, formerly known as Open Orphan plc, a leading contract research organization specializing in human challenge clinical trials for infectious and respiratory diseases, has announced that Allan Rankin no longer holds a disclosable interest in the company’s issued share capital. The organization, recognized for its rapid growth, offers comprehensive early clinical development services and operates the world’s largest commercial human challenge trial facility in Canary Wharf, London. With a diverse client base that includes top global biopharma companies, hVIVO continues to expand its service offerings and its unique portfolio of human challenge models.
For further insights into GB:HVO stock, check out TipRanks’ Stock Analysis page.
